Journal for ImmunoTherapy of Cancer (Nov 2023)

60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407

Hannes Loferer,
Stefan Bissinger,
Ilona-Petra Maser,
Sonja Lacher,
Marisa Stebegg,
Vincent Piras,
Barbara Kracher,
Kai Quirin,
Murray Yule

Affiliations

Hannes Loferer: 1iOmx Therapeutics AG, Martinsried/Munich, Germany
Stefan Bissinger: 1iOmx Therapeutics AG, Martinsried/Munich, Germany
Ilona-Petra Maser: 1iOmx Therapeutics AG, Martinsried/Munich, Germany
Sonja Lacher: 1iOmx Therapeutics AG, Martinsried/Munich, Germany
Marisa Stebegg: 1iOmx Therapeutics AG, Martinsried/Munich, Germany
Vincent Piras: 2Evotec SAS, Toulouse, France
Barbara Kracher: 3Evotec GmbH, Neuried/Munich, Germany
Kai Quirin: 1iOmx Therapeutics AG, Martinsried/Munich, Germany
Murray Yule: 1iOmx Therapeutics AG, Martinsried/Munich, Germany

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.0060
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal